Survival

Peter Dutton’s plan to cut the 2030 climate target would be an own goal for Australia’s Pacific ambitions

Retrieved on: 
Tuesday, June 18, 2024

But Australia remains embroiled with China in a tussle for influence in the Pacific – a fight in which climate ambition is key.

Key Points: 
  • But Australia remains embroiled with China in a tussle for influence in the Pacific – a fight in which climate ambition is key.
  • That’s why, at a diplomatic level, we should be concerned about Opposition leader Peter Dutton’s suggestion the Coalition would abandon Australia’s 2030 emissions target should it win the next election.
  • Even if the Coalition wins office, Dutton is unlikely to have the Senate numbers to scrap the 2030 target.

How is China travelling on the Paris Agreement?

  • China installed more solar capacity in 2023 than the whole world did in 2022, and is expected to install even more this year.
  • Under its current Paris Agreement target, China plans to reach more than 1,200 gigawatts of installed wind and solar power by 2030.
  • China also pledged to reach peak emissions before 2030 and there are signs this target has already been met.
  • Now, China has indicated it may strengthen its 2030 target, and at the same time will set a new 2035 target.

China’s growing presence in the Pacific

  • At the same time as making good progress on its climate commitments, China has been expanding its presence in the Pacific.
  • In recent years China has become a major provider of aid for Pacific island countries, especially for much-needed infrastructure projects.
  • China is also seeking new security arrangements in the Pacific.

For our Pacific neighbours, climate action is crucial

Cancer is affecting more young people than ever before: How health care can learn to meet their needs

Retrieved on: 
Tuesday, June 18, 2024

By definition, adolescents and young adults (AYAs) are people diagnosed with cancer between the ages of 15 and 39.

Key Points: 
  • By definition, adolescents and young adults (AYAs) are people diagnosed with cancer between the ages of 15 and 39.
  • What is known is that cancer is different for adolescents and young adults than it is for children or older adults.
  • However, only 0.4 per cent of all cancer research funding focuses on young adult cancer.

Distinct challenges for younger patients

  • Having cancer as a young person changes you in profound ways.” ~young adult navigating cancer Not only are patients in this age group navigating the challenges of facing a life-altering cancer diagnosis, they are also often navigating other challenges distinct to their life stage.
  • For AYAs with diverse intersectionalities (for example, race, gender, sex, class, age, disability, geography, health status), the challenges are further amplified and there is limited focus on understanding their distinct needs.
  • In Canada, although young people represent four per cent of patients diagnosed each year, there are few oncologic and supportive programs specific to this age group.

Inspiring change in B.C.

  • The Anew Research Collaborative, based at Royal Roads University in Victoria, is led by Cheryl Heykoop, Michael Smith Health Research B.C.
  • Anew is working with adolescents and young adults, BC Cancer, BC Children’s Hospital, related care providers and partners to create change for AYAs.
  • This approach acknowledges that adolescents and young adults are experts of their own cancer experiences who, in engaging creatively with cancer care providers, inspire meaningful change.

Dedicated care for young patients

  • This collaborative effort to streamline fertility care is impressive with BC Cancer, BC Children’s Hospital, Vancouver General Hospital and Yukon hospitals working together with B.C./Yukon AYAs, Anew and related care providers.
  • Amidst the devastating realities of being diagnosed with cancer as an adolescent or young adult in B.C., there are promising times ahead.
  • Patients, families, health-care providers and researchers can learn more and register for updates at Anew’s website.

Mothers have long been absent from dystopian stories. ‘Maternal cli-fi’ is changing the narrative

Retrieved on: 
Tuesday, June 18, 2024

I am palpably reminded of this watching the opening scenes of Mahalia Belo’s assured debut feature film The End We Start From.

Key Points: 
  • I am palpably reminded of this watching the opening scenes of Mahalia Belo’s assured debut feature film The End We Start From.
  • Skilfully adapted by Alice Birch from Megan Hunter’s 2017 novella, the film opens in the bathroom of a London townhouse.
  • Nonetheless, it is hard not to read the scene as a nod to the long cinematic history of erasing mothers.

Motherhood as catastrophe

  • Centring a survival story on a new mother has its roots in mainstream portrayals of motherhood as difficult and depleting.
  • The film begins dramatically, pairing the breaking of the woman’s waters with the heavy deluge pounding London.
  • In pairing motherhood with mother nature, the film depicts birth as both a beginning and an end, a seismic event that, however ordinary, feels biblical in scale.
  • What distinguishes maternal cli-fi from climate fiction more broadly is its use of motherhood as a narrative strategy to raise ethical questions about the future of the world and our place in it.

Is it OK to still have children?

Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma

Retrieved on: 
Sunday, June 16, 2024

TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that 14-month median follow-up data from the pivotal Phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory (R/R) multiple myeloma (MM) were shared during an oral presentation at the European Hematology Association (EHA) Congress 2024 and published in the Journal of Clinical Oncology. These longer-term results show a deepening of responses following the 11-month median follow-up data presented at the American Association for Cancer Research Annual Meeting in April. Linvoseltamab is an investigational bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing.

Key Points: 
  • These longer-term results show a deepening of responses following the 11-month median follow-up data presented at the American Association for Cancer Research Annual Meeting in April.
  • Linvoseltamab is an investigational bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing.
  • “Previous results from LINKER-MM1 have demonstrated that linvoseltamab has compelling efficacy characterized by deep and durable responses.
  • “Additionally, a study using US-based electronic health record data to indirectly compare linvoseltamab to real-world standard-of-care treatment also support the overall body of evidence for this investigational medicine in heavily pretreated multiple myeloma.

6 New Games Unveiled and AI Playmate Launched: YOOZOO GAMES 616 "Youth Day" to Continue Global Expansion

Retrieved on: 
Sunday, June 16, 2024

YOOZOO GAMES pioneered a global live stream experience, broadcasting the 8th annual "616 Youth Day" celebrations to a worldwide audience for the first time.

Key Points: 
  • YOOZOO GAMES pioneered a global live stream experience, broadcasting the 8th annual "616 Youth Day" celebrations to a worldwide audience for the first time.
  • During this event, YOOZOO GAMES launched its first AI product, “AI Playmate”, and initiated a campaign for its character design.
  • Celebrating with Millions of Global Players, YOOZOO GAMES Deepens Its Global Strategy
    This year's 616 Youth Day was celebrated globally for the first time through a live broadcast, engaging players of all YOOZOO GAMES products and enhancing player rewards.
  • To mark this year’s 616 Youth Day, YOOZOO GAMES introduced its first AI product, “AI Playmate”, making its debut during the live stream.

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leuk

Retrieved on: 
Friday, June 14, 2024

The TP53m AML and HR-MDS patients we have treated represent a high-risk group with short duration of complete remission and overall survival when treated with azacitidine alone.

Key Points: 
  • The TP53m AML and HR-MDS patients we have treated represent a high-risk group with short duration of complete remission and overall survival when treated with azacitidine alone.
  • Median overall survival and duration of remission have not yet been achieved, and we look forward to sharing additional durability data later this year.
  • Key takeaways: Additional interim efficacy observed for SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML.
  • To listen to the live webcast, please visit the Investor Relations page of the Shattuck Labs website here .

Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress

Retrieved on: 
Friday, June 14, 2024

The study being presented evaluated the molecular basis of inhibition of the stem cell factor (SCF)/c-Kit signaling pathway via briquilimab and its functional impact on healthy human HSC survival, proliferation, and differentiation.

Key Points: 
  • The study being presented evaluated the molecular basis of inhibition of the stem cell factor (SCF)/c-Kit signaling pathway via briquilimab and its functional impact on healthy human HSC survival, proliferation, and differentiation.
  • Results from the study demonstrate that blocking of SCF/c-Kit signaling by briquilimab does not cause apoptosis of HSCs, and that HSCs cultured in the presence of briquilimab differentiate directly into CD34- cells with higher c-Kit expression and without increased CD38 expression.
  • “We are pleased to present preclinical data demonstrating the effect of c-Kit inhibition on the HSC compartment,” said Wendy Pang, M.D., Ph.D., Senior Vice President, Research and Translational Medicine of Jasper.
  • “While blocking of SCF/c-Kit signaling by briquilimab does lead to mast cell apoptosis, it is important that it does not have a similar effect on healthy HSCs, and these data indicate that briquilimab instead skews them towards a distinct alternative HSC differentiation pathway.

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

Retrieved on: 
Friday, June 14, 2024

The overall response rate (ORR) (Complete Response/CRi) in all patients who received obe-cel in the FELIX study was 78% (99/127 patients).

Key Points: 
  • The overall response rate (ORR) (Complete Response/CRi) in all patients who received obe-cel in the FELIX study was 78% (99/127 patients).
  • At the February 7, 2024, data cut-off date, the majority of ongoing responders showed durable responses.
  • These data support the potential of a long-term plateau of survival outcomes in patients receiving obe-cel.
  • Choice of bridging therapy prior to obe-cel treatment, though influenced by clinical care variables, may impact outcomes for patients with R/R B-ALL.

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

Retrieved on: 
Thursday, June 13, 2024

The data from INB-100 demonstrated that 100% of evaluable leukemia patients (n=10) remained alive, progression-free, and in durable CR through one year as of May 31, 2024.

Key Points: 
  • The data from INB-100 demonstrated that 100% of evaluable leukemia patients (n=10) remained alive, progression-free, and in durable CR through one year as of May 31, 2024.
  • The trial has been expanded to enroll an additional ten patients at Dose Level 2 (DL2), the recommended Phase 2 dose.
  • Enrollment and treatment of patients into the expansion cohort is ongoing, with updated data expected in late 2024 and 2025.
  • “100% of evaluable patients remain in complete remission at one year of follow-up.

PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer

Retrieved on: 
Wednesday, June 12, 2024

PRINCETON, N.J., June 12, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today provided a data update from its ongoing VERSATILE-002 Phase 2 clinical trial. VERSATILE-002 is evaluating Versamune® HPV + KEYTRUDA® (pembrolizumab) in patients with HPV16-positive head and neck squamous cell cancer (“HNSCC”).

Key Points: 
  • VERSATILE-002 is evaluating Versamune® HPV + KEYTRUDA® (pembrolizumab) in patients with HPV16-positive head and neck squamous cell cancer (“HNSCC”).
  • The Kaplan-Meier analysis described below captures the survival data for immune checkpoint inhibitor (“ICI”) naïve patients from the ongoing VERSATILE-002 Phase 2 clinical trial.
  • All patients whose data are reported in the Kaplan-Meier analysis are properly censored to confirm their follow-up and survival status.
  • PDS01ADC is the Company’s tumor-targeted IL-12-fused antibody-drug conjugate (“ADC”), which has shown promise in ongoing Phase 2 clinical trials including a Phase 2 clinical trial of Versamune® HPV + PDS01ADC + an investigational ICI conducted by the National Cancer Institute.